Aurora Cannabis Reports Revenues Of $75.5 Million For Q3, Doesn’t Provide Net Loss Figure

Aurora Cannabis (TSX: ACB) (NYSE: ACB) reported third quarter earnings after the bell today, electing to only file select data in the news release before the scheduled conference call. The firm reported net revenues of $75.5 million for the quarter, while not publishing an earnings per share or net loss figure. Adjusted EBITDA for the quarter was reported as being -$50.9 million for the period.

Net revenue overall was recorded as being $78.4 million, before provisions of $2.9 million were taken into account. Cannabis revenue during the quarter was $69.6 million. Of those revenues, $41.5 million was associated with the recreational cannabis market, $27.0 million was in the medical market, while the international medical cannabis market netted $4.0 million in revenues for Aurora.

In terms of associated expenses to achieve these revenues, Aurora has claimed that it is on the path to a run-rate of $40 – $45 million per quarter for selling, general and administrative expenses, despite spending a total of $80.1 million during the quarter in this expense category. Further expenditure data has not as of yet been provided.

In terms of Aurora’s cash position, the company reported $230.2 million as of March 31, an increase from December’s figure of $156.3 million. That increase was primarily driven by the company raising $206.4 million through its at-the-market offering and $22.0 million debt, which was partially offset by burning through $154.5 million during the quarter – which, unbelievably, was a significant quarter over quarter improvement.

Lastly, Aurora produced 36,207 kilograms of cannabis during the quarter, while only selling 12,729 kilograms.

Full financials have yet to be release by the company.

Aurora Cannabis last traded at $9.20 on the TSX.


Information for this briefing was found via Sedar and Aurora Cannabis. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Newmont Q1 Earnings: A Billion In Free Cash Flow… A Month!

The Biggest Undeveloped Gold Project Still Needs One Thing | Rudi Fronk – Seabridge

The Silver Market May Be Closer to Breaking Than It Looks | Andy Schectman

Recommended

Silver47 Pulls High-Grade Gold and Silver Assays from Nevada Vein Network At Kennedy

Canadian Gold Resources Taps Chernin as Interim CEO in Planned Transition

Related News

Cronos Group Licenses IP From Aurora Cannabis, 22nd Century Group Related To Biosynthesis

Aurora Cannabis (TSX:ACB) has reportedly entered into a licensing arrangement with 22nd Century Group (NASDAQ:...

Wednesday, December 15, 2021, 09:21:00 AM

Aurora Cannabis Dumps 23% Stake In Alcanna At 80% Loss

Aurora Cannabis (TSX: ACB) (NYSE: ACB) continues to liquidate its assets as it tries to...

Wednesday, June 3, 2020, 08:46:41 AM

Aurora Cannabis: Canaccord Anticipates Q2 Revenues Of $69.5 Million

On Thursday, February 11th, Aurora Cannabis (TSX: ACB) (NYSE: ACB) is scheduled to release their...

Tuesday, February 9, 2021, 04:01:00 PM

Aurora Cannabis Converts 99% of $230 Million Convertible Debenture Into 69 Million Shares

Aurora Cannabis (TSX: ACB) (NYSE: ACB) announced this morning that their early conversion option on...

Monday, November 25, 2019, 09:37:40 AM

Aurora Cannabis Names New CEO, Announces Over $1.8 Billion In Q4 Writedowns On Declining Revenues

Aurora Cannabis (TSX: ACB) (NYSE: ACB) this morning finally announced their new CEO, whom as...

Tuesday, September 8, 2020, 08:22:47 AM